Y H Mao, T R Cao, L H Chen, J W Hu, L Y Zhou, Q H Ma, X Y Song, K Yuan
{"title":"[Analysis of problems and management of <i>in vitro</i> diagnostic reagent clinical trials in medical laboratory].","authors":"Y H Mao, T R Cao, L H Chen, J W Hu, L Y Zhou, Q H Ma, X Y Song, K Yuan","doi":"10.3760/cma.j.cn112150-20240408-00284","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical trials are an important method for evaluating the safety and efficacy of <i>in vitro</i> diagnostic reagents, and are a key basis for product registration review and approval. In order to strengthen the management of clinical trials of <i>in vitro</i> diagnostic reagents, the National Medical Products Administration and relevant departments have formulated a series of regulations at the regulatory level, and require applicants and clinical trial institutions to establish a quality management system for clinical trials of <i>in vitro</i> diagnostic reagents. Medical laboratory is the main department and implementer of <i>in vitro</i> diagnostic reagent clinical trials in medical institutions. In recent years, with the rapid development of the <i>in vitro</i> diagnostic industry, the clinical trial projects of <i>in vitro</i> diagnostic reagents conducted by medical laboratory have been increasing day by day. However, there are currently few discussions on the clinical trial of <i>in vitro</i> diagnostic reagents from the perspective of researchers. Therefore, this article summarizes the characteristics of clinical trials of <i>in vitro</i> diagnostic reagents, analyzes the problems and difficulties in conducting clinical trials of <i>in vitro</i> diagnostic reagents in current medical laboratories, and introduces the laboratory's experience in management; to provide reference for medical testing laboratories that have not yet conducted or have already conducted clinical trials of <i>in vitro</i> diagnostic reagents, in order to improve the quality and efficiency of clinical trials.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":"58 9","pages":"1473-1477"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华预防医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112150-20240408-00284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Clinical trials are an important method for evaluating the safety and efficacy of in vitro diagnostic reagents, and are a key basis for product registration review and approval. In order to strengthen the management of clinical trials of in vitro diagnostic reagents, the National Medical Products Administration and relevant departments have formulated a series of regulations at the regulatory level, and require applicants and clinical trial institutions to establish a quality management system for clinical trials of in vitro diagnostic reagents. Medical laboratory is the main department and implementer of in vitro diagnostic reagent clinical trials in medical institutions. In recent years, with the rapid development of the in vitro diagnostic industry, the clinical trial projects of in vitro diagnostic reagents conducted by medical laboratory have been increasing day by day. However, there are currently few discussions on the clinical trial of in vitro diagnostic reagents from the perspective of researchers. Therefore, this article summarizes the characteristics of clinical trials of in vitro diagnostic reagents, analyzes the problems and difficulties in conducting clinical trials of in vitro diagnostic reagents in current medical laboratories, and introduces the laboratory's experience in management; to provide reference for medical testing laboratories that have not yet conducted or have already conducted clinical trials of in vitro diagnostic reagents, in order to improve the quality and efficiency of clinical trials.
期刊介绍:
Chinese Journal of Preventive Medicine (CJPM), the successor to Chinese Health Journal , was initiated on October 1, 1953. In 1960, it was amalgamated with the Chinese Medical Journal and the Journal of Medical History and Health Care , and thereafter, was renamed as People’s Care . On November 25, 1978, the publication was denominated as Chinese Journal of Preventive Medicine . The contents of CJPM deal with a wide range of disciplines and technologies including epidemiology, environmental health, nutrition and food hygiene, occupational health, hygiene for children and adolescents, radiological health, toxicology, biostatistics, social medicine, pathogenic and epidemiological research in malignant tumor, surveillance and immunization.